NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds for the treatment of cancer and fibrosis, has entered into an agency agreement with Sanghyon Chemical to represent the Company with major pharmaceutical companies in Korea. Sanghyon Chemical will provide for the registration of DAVANAT® with the Korean FDA and marketing and sales support for the licensing and distribution of DAVANAT® to treat cancer with chemotherapy drugs.
